Literature DB >> 14504914

Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters.

Luigi Caserta1, Laura de Magistris, Mario Secondulfo, Giancarlo Caravelli, Gabriele Riegler, Giovanna Cuomo, Salvatore D'Angelo, Caterina Naclerio, Gabriele Valentini, Romano Carratù.   

Abstract

OBJECTIVE: The aim of this study was to assess intestinal permeability (IP) in patients with systemic sclerosis (SSc) and to relate the results with general disease activity and gastrointestinal involvement.
METHODS: Twenty-eight females and four males were studied. Patients with severe gastrointestinal involvement were excluded. Thirty-three healthy volunteers served as controls. Intestinal permeability was assessed by means of the orally administered cellobiose/mannitol sugar (Ce/Ma) test. Intestinal transit time (ITT) was investigated with the H2-lactulose breath test.
RESULTS: The mean value of IP in 32 SSc patients was significantly higher than in 33 controls ( P<0.05), although it fell within the normal range. Eleven patients showed abnormally high individual IP values (>0.028) that significantly correlated to disease duration ( r=0.73). Altered IP was associated with the higher but not statistically relevant presence of anti-Scl70 antibodies (9/11) and to more severe gastrointestinal involvement. More than half of the SSc patients showed slower orocecal transit times on the H2 breath test. In particular, delayed ITT was observed in 60% of patients with increased IP and in all patients with moderate gastrointestinal involvement according to the scleroderma severity scale.
CONCLUSION: Intestinal permeability was altered in 11/32 SSc patients. Correlations between increased IP and duration of disease and degree of gastrointestinal involvement appear to support the hypothesis of secondary involvement of the intestinal barrier, and the presence of anti-Scl70 antibodies in 82% of the patients with higher IP clearly reinforces the hypothesis of an altered immune response in these subjects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504914     DOI: 10.1007/s00296-003-0286-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  22 in total

Review 1.  Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients.

Authors:  Clodoveo Ferri; Gabriele Valentini; Franco Cozzi; Marco Sebastiani; Claudio Michelassi; Giovanni La Montagna; Arianna Bullo; Massimiliano Cazzato; Enrico Tirri; Franca Storino; Dilia Giuggioli; Giovanna Cuomo; Mara Rosada; Stefano Bombardieri; Silvano Todesco; Giuseppe Tirri
Journal:  Medicine (Baltimore)       Date:  2002-03       Impact factor: 1.889

2.  How do we correctly investigate intestinal permeability?

Authors:  M Secondulfo; L de Magistris; R Carratù
Journal:  Dig Liver Dis       Date:  2002-07       Impact factor: 4.088

3.  Altered mannitol absorption in diabetic children.

Authors:  L De Magistris; M Secondulfo; D Iafusco; A G Carbone; A Urio; G Pontoni; R Carratu
Journal:  Ital J Gastroenterol       Date:  1996 Jul-Aug

4.  A disease severity scale for systemic sclerosis: development and testing.

Authors:  T A Medsger; A J Silman; V D Steen; C M Black; A Akesson; P A Bacon; C A Harris; S Jablonska; M I Jayson; S A Jimenez; T Krieg; E C Leroy; P J Maddison; M L Russell; R K Schachter; F A Wollheim; H Zacharaie
Journal:  J Rheumatol       Date:  1999-10       Impact factor: 4.666

5.  Investigation of small bowel transit time in man utilizing pulmonary hydrogen (H2) measurements.

Authors:  J H Bond; M D Levitt; R Prentiss
Journal:  J Lab Clin Med       Date:  1975-04

6.  Cellobiose/mannitol sugar permeability test complements biopsy histopathology in clinical investigation of the jejunum.

Authors:  S Strobel; W G Brydon; A Ferguson
Journal:  Gut       Date:  1984-11       Impact factor: 23.059

7.  Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study.

Authors:  H Mielants; E M Veys; S Goemaere; K Goethals; C Cuvelier; M De Vos
Journal:  J Rheumatol       Date:  1991-10       Impact factor: 4.666

8.  Malabsorption caused by coeliac disease in patients who have scleroderma.

Authors:  C Marguerie; S Kaye; T Vyse; C Mackworth-Young; M J Walport; C Black
Journal:  Br J Rheumatol       Date:  1995-09

9.  [Gastrointestinal involvement in progressive systemic scleroderma].

Authors:  C Folwaczny; U Rothfuss; R L Riepl; P Lehnert; H Bloching; M Meurer; U Karbach
Journal:  Z Gastroenterol       Date:  1995-11       Impact factor: 2.000

10.  Intestinal permeability in patients with yersinia triggered reactive arthritis.

Authors:  R Lahesmaa-Rantala; K E Magnusson; K Granfors; R Leino; T Sundqvist; A Toivanen
Journal:  Ann Rheum Dis       Date:  1991-02       Impact factor: 19.103

View more
  6 in total

1.  [Gastrointestinal involvement in systemic sclerosis. An underestimated complication].

Authors:  P Saar; T Schmeiser; I H Tarner; U Müller-Ladner
Journal:  Hautarzt       Date:  2007-10       Impact factor: 0.751

2.  Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats.

Authors:  Tammara Watts; Irene Berti; Anna Sapone; Tania Gerarduzzi; Tarcisio Not; Ronald Zielke; Alessio Fasano
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

3.  Gastrointestinal manifestations in Hungarian scleroderma patients.

Authors:  Szilvia Szamosi; Zoltán Szekanecz; Gabriella Szucs
Journal:  Rheumatol Int       Date:  2006-06-13       Impact factor: 2.631

4.  Profile of gastrointestinal involvement in patients with systemic sclerosis.

Authors:  T Schmeiser; P Saar; D Jin; M Noethe; A Müller; N Soydan; P D Hardt; C Jaeger; O Distler; E Roeb; R G Bretzel; U Müller-Ladner
Journal:  Rheumatol Int       Date:  2011-07-19       Impact factor: 2.631

Review 5.  Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis.

Authors:  Daniel E Furst; Yolanda Braun-Moscovic; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

6.  Comparing Clinical, Imaging, and Physiological Correlates of Intestinal Pseudo-Obstruction: Systemic Sclerosis vs Amyloidosis and Paraneoplastic Syndrome.

Authors:  Rahul Pamarthy; Antonio Berumen; Margaret Breen-Lyles; Madhusudan Grover; Ashima Makol
Journal:  Clin Transl Gastroenterol       Date:  2020-08       Impact factor: 4.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.